INFORMATION DISCLOSURE CITATION			Docket Number (Optional) RDID 02010 US			Application Number TBD					
(Use several sheets if necessary)				Applicants(s) Ghoshal et al.							
				Filing Date December 10, 2003 Group Art Unit							
P	Ref	Document Number		U.S. PATENT DOCUMENTS							
Examiner Initials	Kei			Date		Name	Clas	s	Subclass	Filing Date (If Appropriate)	
<u>/SH/</u>		5,633,405	5/27	7/97	Thompso	n et al.	564		321		
				· · · · · · · · · · · · · · · · · · ·	ļ		ļ				
		<u> </u>									
					<u> </u>						
					<u> </u>		 				
				·			 				
							 				
	 		 .				 				
							-				
	 						 		-		
	1	<u> </u>	•	FOREIC	N PATENT	DOCUMENTS	<u>i</u>	-	<u> </u>	<u> </u>	
	Ref	Document Number		Date		Country	Clas	s	Subclass	Translation	
	ļ				 						
	ļ						ļ				
	ļ				-		 				
	<u> </u>	Other Do	Cume	ents (Includ	ling Author	Title, Date, Perti	nent Pag	oc Et	L		
	<u> </u>	Mutlib et al. "Identif								mid (c o o)	
/SH/		Chromatography/Ma									
		Metabolism of Efavirenz". Drug Metabolism and Disposition, Vol 27, No. 11, pg 1319-1333 Marzolini et al., "Efavirenz plasma levels can predict treatment failure and central nervous system									
	ļ	side effects in HIV-1-infected patents". AIDS 2001, 15: 71-75 Singh et al., "Cesium Fluoride Catalyzed Trifluoromethylation of Esters, Aldehydes, and Ketones with (Trifluoromethyl) Trimethylsilane", J. Org Chem 1999, 64, 2873-2876 Radesca, et al., "Synthesis of HIV-1 Reverse Transcriptase Inhibitor DMP 266", Synthetic						•			
								des, and Ketones			
	<u> </u>										
l								Synthetic			
Communications, 27(24), 4373-4384 (1997)											
		Zhuyin Li et al., "New Synthesis and Characterization of (+) Lysergic Acid Diethylamide (LSD) Derivatives and the Development of a Microparticle-Based Immunoassay for the Detection of LSD and Its Metabolites", Bioconjugate Chem. 1997, 8, 896-905						nylamide (LSD)			
								Detection of			
	ļ	Prakash, G.K., Yudi	n Al	C "Perfli	ijugaie Cile ioroalkylati	on with Orga	nosilica	n D	eagents" C	hem Rev 1007	
		97, 757-786		12, 101110	orounkylut	on with Orga	mosmice)]] [X	cagonis, C	mem Rev 1997,	
\/		Patel, et al., "Synthe	sis a	nd Evalu	ation of An	alogs of Efav	irenz (S	Susti	va TM) as H	IV-1 Reverse	
<u> </u>		Transcriptase Inhibit									
Examine	r /S	hafiqul Haq/				Date Consider		1/20			
EXAMINE	R: Initia	al if citation considered, whether	or not	citation is in	conformance wit	h MPEP Section 609	9; Draw lin	e throu	gh citation if not	in conformance and not	

FORM PTO-A820

P09A/REV04

Sheet 1 of 1

WEMMH/SB/08A (4/03)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

ດf

Complete if Known					
Application Number	10/732,767				
Filing Date	December 10, 2003				
First Named Inventor	Mitali GHOSHAL				
Group Art Unit	1621				
Examiner Name	TBD				
Attorney Docket Number	RDID02010US				

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
		:			
					,
<u> </u>					

Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
/SH/_		EP 1470825 A1	10/27/2004			t
/SH/		WO03/006506 A2	1/23/2003	G,	· · · · · · · · · · · · · · · · · · ·	
			ĺ	•		
·						Г
						П
						İ

		·	
Examiner Signature	/Shafiqul Haq/	Date Considered	09/11/2007

EXAMINER: Initial II reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.s. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the emperor must precede the serial number of the patent document. ⁵ Kind of document by the apOpropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	L ₃
/SH/		Akeb, F. et al., "Quantification of plasma and intracellular levels of the HIV protease inhibitor ritonavir by competitive ELISA," Journal of Immunological Methods 263 (2002) 1-9	
/SH/		Rezk, N. et al., "Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection," Journal of Chromatography B, 774 (2002) 79-88	
			_
			_
,			_
		•	
			_
Examiner Signature	/S	hafiqul Haq/ Date Considered 09/11/2007	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.